PRIME MEDICINE INC (PRME)
Health Care · Gene Editing / Gene Therapy · NASDAQ
A biotechnology company developing next-generation gene editing therapies based on its proprietary Prime Editing platform to cure serious genetic diseases.
What PRIME MEDICINE INC does
Prime Medicine is a clinical-stage biotechnology company focused on developing therapeutic products based on its Prime Editing technology, a gene editing platform designed to address unmet medical needs. The company is advancing multiple product candidates across various therapeutic areas through preclinical studies and clinical trials. Prime Medicine generates limited revenue through collaboration agreements while investing substantially in research and development to advance its pipeline of prime editing-based therapeutics.
Themes: gene editing, genetic diseases, genomics, biotechnology
Fundamentals
- Price$3.39 as of 2026-08-21 close
- Market cap$615M as of 2026-08-21
- 1-year return+5.3% 2025-08-21 close $3.22 → 2026-08-21 close $3.39
- P/En/a negative earnings
- Net margin-4613.1% as of 2026-08-24
- ROE-188.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-17.9% as of 2026-08-24
- Beta2.31 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How PRME compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PRIME MEDICINE INC looks technically
PRIME MEDICINE INC (PRME) is trading 5.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 108 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 51.2% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 5.6% below its 200-day average, the long-term trend line — a long-term downtrend | -5.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.28 | $3.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.59 | $3.59 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 108 trading days ago — a "death cross", a bearish long-term signal | 108 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 54.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($2.82 to $3.59) — its "stochastic" reading is 74 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 74.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.94 | $6.94 |
|---|---|---|
| From the 52-week high | it is 51.2% below its 52-week high (its highest price of the past year) | -51.1% |
| Above the 52-week low | it is 27.0% above its 52-week low (its lowest price of the past year) | +27.0% |
| Below the 52-week high | it is 51.2% below its highest point of the past year | 51.1% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $21.73 (set on 2022-11-14) | $21.73 |
| Given back of the 52-week move | over the past year its closes ranged ($2.70 to $6.67), and it has recovered roughly a quarter of its fall from last year’s high — 17% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.15 to $5.28. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 17.4% |
| From the all-time high | it is 84.4% below its all-time high | -84.4% |
| Nearest price level | it is trading 1.2% above a support level at $3.35 — a price it turned at twice since 2025-01-24, most recently on 2025-02-19. Since 2024-08-21 it has 7 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.2% |
| All-time low | its lowest closing price on record is $1.11 (set on 2025-05-20) | $1.11 |
| Above the all-time low | it is 205.4% above its all-time low | +205.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 84% of it) | 16th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2428 between its high and its low — about 7.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2428 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.79 and $3.43 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.79 – $3.11 – $3.43 |
| Typical daily range (% of price) | its price moves about 7.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.2% |
| Stretch from the 200-day average | it is trading 0.8 daily ranges below its 200-day average price (5.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.23× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 3.8% since the prior reading | +3.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.04 toward buy |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Open gap | it gapped 3.1% below the previous close 1 session ago and has not traded back through the level it left behind at 3.54 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -3.1% |
| Gap filled | a 2.2% gap down opened on 2026-08-18 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 6.3 percentage points (the stock gained 8.7% while the market gained 2.3%) | +6.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.8 percentage points (the stock gained 14.9% while the market gained 3.1%) | +11.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 7.4 percentage points (the stock gained 3.7% while the market gained 11.1%) | -7.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 15.2 percentage points (the stock gained 5.3% while the market gained 20.5%) | -15.2% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.5% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.7% of the share price. | -9.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.58 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -5.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $3.25 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +4.2% |
Price levels it has turned at before
PRME last closed at $3.39 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.35 | Support | 1.2% below the last close | turned there twice · 2025-01-24 to 2025-02-19 |
| $3.29 | Support | 3.1% below the last close | turned there four times · 2024-10-02 to 2026-08-10 |
| $3.57 | Resistance | 5.3% above the last close | turned there four times · 2024-11-25 to 2026-05-29 |
| $3.16 | Support | 6.7% below the last close | turned there twice · 2025-11-14 to 2026-02-17 |
| $3.73 | Resistance | 10.0% above the last close | turned there three times · 2025-07-17 to 2026-01-20 |
| $3.83 | Resistance | 12.9% above the last close | turned there twice · 2024-10-31 to 2026-03-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · trendless / choppy (low ADX) · Analyst price target recently RAISED · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.54 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$7.30 range $4.25 – $11.00; median $8.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PRME
- Consensus EPS estimate-$0.2325 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in the early stages of development and has no products approved for sale, leading to significant accumulated deficits and potential need for additional capital.","The company's reliance on its proprietary Prime Editing technology presents significant scientific, regulatory, and intellectual property risks."]
What changed in the latest 10-Q
AI-assisted comparison of PRME's 10-Q filed 2026-05-07 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for 'Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations' changed from 25 (2025-11-07) to 22 (2026-05-07)
- Page number for 'Item 3. Quantitative and Qualitative Disclosures About Market Risk' changed from 34 (2025-11-07) to 29 (2026-05-07)
- Page number for 'Item 4. Controls and Procedures' changed from 34 (2025-11-07) to 30 (2026-05-07)
- Page number for 'PART II - OTHER INFORMATION' changed from 36 (2025-11-07) to 31 (2026-05-07)
- Page number for 'Item 1. Legal Proceedings' changed from 36 (2025-11-07) to 31 (2026-05-07)
- Notes:
- These appear to be table of contents entries showing only page number shifts; no substantive content changes are visible in the provided text excerpts
Risk Factors
- Added:
- Reference to trademark application intent added in newer filing
- Clarification that trademarks may appear without ®, SM, ™ symbols in newer filing
- Removed:
- Reference to 'Annual Report on Form 10-K' removed; replaced with 'Quarterly Report on Form 10-Q' in newer filing
- Reworded:
- Newer filing removes detailed stockholders' equity transaction history (public offering details, warrant exercises, restricted stock units) that appeared in older filing for comparative periods
- Newer filing presents shorter comparative period (Q1 2026 vs Q1 2025) versus older filing presenting nine-month and quarterly comparatives (nine months and Q3 2025 vs 2024)
- Balance sheet dates changed from September 30, 2025 and December 31, 2024 (older) to March 31, 2026 and December 31, 2025 (newer)
- Short-term investment — related party line item removed from newer balance sheet presentation
- Accumulated other comprehensive loss/income caption changed from 'Losses' to 'Income (Loss)' in newer filing
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs Q3 2025), which explains many of the financial statement variations
- Document structure and page numbering changed between filings, reflecting different content organization
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for PRME — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding PRME as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 24,202,233
- Reported value $84,223,769
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PRME had 35,003,578 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PRME had 19.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.9 days to cover at the same settlement.
- Reported short interest (shares) 35,003,578
- Short interest (% of shares outstanding) 19.3%
- Prior settlement (shares) 33,536,516
- Reported change 4.37%
- Days to cover (reported) 12.9
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Editas Medicine (EDIT)
- CRISPR Therapeutics (CRSP)
- Intellia Therapeutics (NTLA)
- Beam Therapeutics (BEAM)
- Sangamo Therapeutics (SGMO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PRME vs…
PRIME MEDICINE INC is found in…
Frequently asked questions
What does PRIME MEDICINE INC (PRME) do?
Prime Medicine is a clinical-stage biotechnology company focused on developing therapeutic products based on its Prime Editing technology, a gene editing platform designed to address unmet medical needs. The company is advancing multiple product candidates across various therapeutic areas through preclinical studies and clinical trials.
What sector is PRIME MEDICINE INC (PRME) in?
PRIME MEDICINE INC (PRME) is classified in the Health Care sector. Its industry is Gene Editing / Gene Therapy. It trades on NASDAQ.
Who are PRIME MEDICINE INC's (PRME) competitors?
Notable peers of PRIME MEDICINE INC (PRME) include Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics and Sangamo Therapeutics. This peer set is informational only — not financial advice.
Is PRIME MEDICINE INC (PRME) overbought or oversold right now?
PRIME MEDICINE INC (PRME) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PRME come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.